Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on “Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the

Author:

Landi Doriana12,Centonze Diego12,Marfia Girolama Alessandra12,Capra Ruggero3,Scarpazza Cristina3ORCID

Affiliation:

1. Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine; Tor Vergata University; Rome Italy

2. IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed; Pozzilli Isernia Italy

3. Multiple Sclerosis Center, Spedali Civili di Brescia; Montichiari Brescia Italy

Publisher

Wiley

Subject

Hematology,General Medicine

Reference6 articles.

1. Guidelines on the use of therapeuric apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue;Schwartz;J Clin Apher.,2016

2. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function;Khatri;Neurology.,2009

3. Natalizumab therapy of multiple sclerosis: recommendations of the Mutliple Sclerosis Study Group-Italian Neurological Society;Ghezzi;Neurol Sci.,2011

4. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML;Landi;Neurology.,2017

5. To do or not to do? Plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy;Scarpazza;Ann Neurol.,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3